vs
FNB CORP（FNB）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
FNB CORP的季度营收约是REPLIGEN CORP的1.8倍（$366.0M vs $197.9M），FNB CORP净利率更高（45.9% vs 6.7%，领先39.2%），FNB CORP同比增速更快（13.7% vs 13.6%），FNB CORP自由现金流更多（$99.0M vs $17.6M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 7.1%）
FNB集团是总部位于美国宾夕法尼亚州匹兹堡的多元化金融服务机构，为旗下最大子公司第一国民银行的控股主体，截至2025年12月31日总资产超500亿美元，业务覆盖匹兹堡、巴尔的摩、克利夫兰、华盛顿特区、北卡罗来纳州多座城市及南卡罗来纳州查尔斯顿等核心都会区。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
FNB vs RGEN — 直观对比
营收规模更大
FNB
是对方的1.8倍
$197.9M
营收增速更快
FNB
高出0.0%
13.6%
净利率更高
FNB
高出39.2%
6.7%
自由现金流更多
FNB
多$81.4M
$17.6M
两年增速更快
RGEN
近两年复合增速
7.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $366.0M | $197.9M |
| 净利润 | $168.0M | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | 45.1% | 9.0% |
| 净利率 | 45.9% | 6.7% |
| 营收同比 | 13.7% | 13.6% |
| 净利润同比 | 52.7% | 143.9% |
| 每股收益（稀释后） | $0.47 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FNBRGEN
| Q4 25 | $366.0M | $197.9M | ||
| Q3 25 | $359.0M | $188.8M | ||
| Q2 25 | $348.0M | $182.4M | ||
| Q1 25 | $323.0M | $169.2M | ||
| Q4 24 | $322.0M | $174.1M | ||
| Q3 24 | $323.0M | $154.9M | ||
| Q2 24 | $316.0M | $154.1M | ||
| Q1 24 | $319.0M | $151.3M |
净利润FNBRGEN
| Q4 25 | $168.0M | $13.3M | ||
| Q3 25 | $150.0M | $14.9M | ||
| Q2 25 | $130.0M | $14.9M | ||
| Q1 25 | $117.0M | $5.8M | ||
| Q4 24 | $110.0M | $-30.3M | ||
| Q3 24 | $110.0M | $-654.0K | ||
| Q2 24 | $123.0M | $3.3M | ||
| Q1 24 | $122.0M | $2.1M |
毛利率FNBRGEN
| Q4 25 | — | 52.5% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 50.0% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 50.0% | ||
| Q2 24 | — | 49.8% | ||
| Q1 24 | — | 49.5% |
营业利润率FNBRGEN
| Q4 25 | 45.1% | 9.0% | ||
| Q3 25 | 52.9% | 8.9% | ||
| Q2 25 | 47.7% | 7.6% | ||
| Q1 25 | 45.8% | 3.9% | ||
| Q4 24 | 31.7% | -17.7% | ||
| Q3 24 | 43.3% | -5.1% | ||
| Q2 24 | 49.7% | 1.0% | ||
| Q1 24 | 48.9% | 1.3% |
净利率FNBRGEN
| Q4 25 | 45.9% | 6.7% | ||
| Q3 25 | 41.8% | 7.9% | ||
| Q2 25 | 37.4% | 8.2% | ||
| Q1 25 | 36.2% | 3.4% | ||
| Q4 24 | 34.2% | -17.4% | ||
| Q3 24 | 34.1% | -0.4% | ||
| Q2 24 | 38.9% | 2.2% | ||
| Q1 24 | 38.2% | 1.4% |
每股收益（稀释后）FNBRGEN
| Q4 25 | $0.47 | $0.24 | ||
| Q3 25 | $0.41 | $0.26 | ||
| Q2 25 | $0.36 | $0.26 | ||
| Q1 25 | $0.32 | $0.10 | ||
| Q4 24 | $0.31 | $-0.55 | ||
| Q3 24 | $0.30 | $-0.01 | ||
| Q2 24 | $0.34 | $0.06 | ||
| Q1 24 | $0.32 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5B | $767.6M |
| 总债务越低越好 | $1.9B | $542.2M |
| 股东权益账面价值 | $6.8B | $2.1B |
| 总资产 | $50.2B | $2.9B |
| 负债/权益比越低杠杆越低 | 0.28× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资FNBRGEN
| Q4 25 | $2.5B | $767.6M | ||
| Q3 25 | $2.4B | $748.7M | ||
| Q2 25 | $2.4B | $708.9M | ||
| Q1 25 | $2.4B | $697.2M | ||
| Q4 24 | $2.4B | $757.4M | ||
| Q3 24 | $2.1B | $784.0M | ||
| Q2 24 | $1.9B | $809.1M | ||
| Q1 24 | $1.5B | $780.6M |
总债务FNBRGEN
| Q4 25 | $1.9B | $542.2M | ||
| Q3 25 | $2.1B | $537.9M | ||
| Q2 25 | $2.7B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $3.0B | $525.6M | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $2.1B | — |
股东权益FNBRGEN
| Q4 25 | $6.8B | $2.1B | ||
| Q3 25 | $6.6B | $2.1B | ||
| Q2 25 | $6.5B | $2.1B | ||
| Q1 25 | $6.4B | $2.0B | ||
| Q4 24 | $6.3B | $2.0B | ||
| Q3 24 | $6.2B | $2.0B | ||
| Q2 24 | $6.1B | $2.0B | ||
| Q1 24 | $6.0B | $2.0B |
总资产FNBRGEN
| Q4 25 | $50.2B | $2.9B | ||
| Q3 25 | $49.9B | $2.9B | ||
| Q2 25 | $49.7B | $2.9B | ||
| Q1 25 | $49.0B | $2.9B | ||
| Q4 24 | $48.6B | $2.8B | ||
| Q3 24 | $48.0B | $2.8B | ||
| Q2 24 | $47.7B | $2.9B | ||
| Q1 24 | $45.9B | $2.8B |
负债/权益比FNBRGEN
| Q4 25 | 0.28× | 0.26× | ||
| Q3 25 | 0.32× | 0.26× | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.39× | — | ||
| Q4 24 | 0.48× | 0.27× | ||
| Q3 24 | 0.40× | — | ||
| Q2 24 | 0.33× | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $128.0M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $99.0M | $17.6M |
| 自由现金流率自由现金流/营收 | 27.0% | 8.9% |
| 资本支出强度资本支出/营收 | 7.9% | 4.1% |
| 现金转化率经营现金流/净利润 | 0.76× | 1.93× |
| 过去12个月自由现金流最近4个季度 | $376.0M | $93.9M |
8季度趋势，按日历期对齐
经营现金流FNBRGEN
| Q4 25 | $128.0M | $25.7M | ||
| Q3 25 | $167.0M | $48.1M | ||
| Q2 25 | $123.0M | $28.6M | ||
| Q1 25 | $64.0M | $15.0M | ||
| Q4 24 | $326.0M | $39.2M | ||
| Q3 24 | $-14.0M | $49.3M | ||
| Q2 24 | $85.0M | $42.2M | ||
| Q1 24 | $245.0M | $44.7M |
自由现金流FNBRGEN
| Q4 25 | $99.0M | $17.6M | ||
| Q3 25 | $149.0M | $43.4M | ||
| Q2 25 | $85.0M | $21.5M | ||
| Q1 25 | $43.0M | $11.4M | ||
| Q4 24 | $278.0M | $33.6M | ||
| Q3 24 | $-46.0M | $42.3M | ||
| Q2 24 | $55.0M | $37.4M | ||
| Q1 24 | $216.0M | $36.4M |
自由现金流率FNBRGEN
| Q4 25 | 27.0% | 8.9% | ||
| Q3 25 | 41.5% | 23.0% | ||
| Q2 25 | 24.4% | 11.8% | ||
| Q1 25 | 13.3% | 6.8% | ||
| Q4 24 | 86.3% | 19.3% | ||
| Q3 24 | -14.2% | 27.3% | ||
| Q2 24 | 17.4% | 24.3% | ||
| Q1 24 | 67.7% | 24.0% |
资本支出强度FNBRGEN
| Q4 25 | 7.9% | 4.1% | ||
| Q3 25 | 5.0% | 2.5% | ||
| Q2 25 | 10.9% | 3.9% | ||
| Q1 25 | 6.5% | 2.1% | ||
| Q4 24 | 14.9% | 3.2% | ||
| Q3 24 | 9.9% | 4.5% | ||
| Q2 24 | 9.5% | 3.1% | ||
| Q1 24 | 9.1% | 5.5% |
现金转化率FNBRGEN
| Q4 25 | 0.76× | 1.93× | ||
| Q3 25 | 1.11× | 3.23× | ||
| Q2 25 | 0.95× | 1.92× | ||
| Q1 25 | 0.55× | 2.57× | ||
| Q4 24 | 2.96× | — | ||
| Q3 24 | -0.13× | — | ||
| Q2 24 | 0.69× | 12.70× | ||
| Q1 24 | 2.01× | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
